Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Short-term topiramate treatment does not improve insulin sensitivity or secretion in obese insulin-resistant women.

Sleddering MA, Snel M, Streefland TC, Pijl H, Jazet IM.

Eur J Endocrinol. 2012 Dec;167(6):839-45. doi: 10.1530/EJE-12-0500. Epub 2012 Sep 14.

2.

Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.

Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U.

Int J Obes (Lond). 2007 Jul;31(7):1140-7. Epub 2007 Feb 13.

PMID:
17264849
3.

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.

Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group.

Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410.

PMID:
15486569
4.

Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M.

Int J Obes (Lond). 2007 Jan;31(1):138-46. Epub 2006 May 16.

PMID:
16703004
5.

The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese.

Syvertsen C, Halse J, Høivik HO, Gaullier JM, Nurminiemi M, Kristiansen K, Einerhand A, O'Shea M, Gudmundsen O.

Int J Obes (Lond). 2007 Jul;31(7):1148-54. Epub 2006 Oct 10.

PMID:
17031391
6.

Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.

Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L; OBDM-003 Study Group.

Diabetes Obes Metab. 2007 May;9(3):360-8.

PMID:
17391164
7.

A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.

Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A; OBD-202 Study Group.

Diabetes Care. 2007 Jun;30(6):1480-6. Epub 2007 Mar 15.

PMID:
17363756
8.
9.

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW.

Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8. Erratum in: Lancet. 2011 Apr 30;377(9776):1494.

PMID:
21481449
10.

Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.

Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, Fitchet M.

Am J Cardiol. 2005 Jul 15;96(2):243-51.

PMID:
16018851
11.

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.

Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH.

Obes Res. 2003 Jun;11(6):722-33.

12.

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.

Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B, Sun X, Fitchet M.

Obes Res. 2004 Oct;12(10):1658-69.

13.

Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder.

Claudino AM, de Oliveira IR, Appolinario JC, Cordás TA, Duchesne M, Sichieri R, Bacaltchuk J.

J Clin Psychiatry. 2007 Sep;68(9):1324-32.

PMID:
17915969
14.

Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes.

Paniagua JA, López-Miranda J, Escribano A, Berral FJ, Marín C, Bravo D, Paz-Rojas E, Gómez P, Barcos M, Moreno JA, Pérez-Jiménez F.

Diabetes. 2002 Aug;51(8):2596-603.

15.
16.

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA.

Diabetes Care. 2000 Aug;23(8):1154-61.

17.

Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.

Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL.

Int J Obes Relat Metab Disord. 1997 Feb;21(2):97-102.

PMID:
9043962
18.

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

Diabetes Obes Metab. 2003 May;5(3):180-8.

PMID:
12681025
19.

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion.

Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, Smith W, Soler N, Warsi G, Berg W, Maloney J, Benedetto J, Zhu W, Hohneker J.

Int J Obes (Lond). 2006 Feb;30(2):331-41.

20.

Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study.

McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR; Topiramate Binge Eating Disorder Research Group.

Biol Psychiatry. 2007 May 1;61(9):1039-48. Epub 2007 Jan 29.

PMID:
17258690

Supplemental Content

Support Center